In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mike Ward

London, UK
Mike has been writing, analysing and commenting on the life sciences industry for more than 30 years as a journalist and investment bank analyst. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry's key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year and has appeared on the shortlist for that award on numerous occasions. When not commentating on all things pharma, Mike is engaged actively in pub quizzes, either as a competitor or a compiler. He is also a qualified FA soccer coach.
Advertisement
Set Alert for Articles By Mike Ward

Latest From Mike Ward

TikoMed Platform Boosts Regenerative Stem Cell Therapy Outcomes

TikoMed founder and CEO Adam Bruce talks to Scrip during BIO-Europe Spring about how the company's IBsolvMIR platform has the potential to improve the viability of cells prior to transplantation.

Platform Technologies Regenerative Medicine

InteRNA CEO On Cancer Monotherapy Ambition For Lead Drug

Roel Schaapveld, CEO of InteRNA, chats with Scrip on the sidelines of the 2018 BIO-Europe Spring partnering event about upcoming milestones for the company's RNA pipeline.

Business Strategies Clinical Trials

Oncology Venture Differentiates Using Big Data Systems Biology

With six oncology assets in Phase II/III ready for outlicensing, Oncology Venture is now looking to take additional programs on board.

Business Strategies Financing

Experts Challenge GSK Triple Inhaled COPD Therapy Claims

While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with COPD in NEJM, two clinicians in an accompanying editorial argue that the trial falls short of providing robust evidence for switching strategy.

Clinical Trials Research & Development

TVM Raises White Flag On Biovertis & Morphochem

Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4% stake worth €900,000. Since their formation, Biovertis and Morphochem have had more than $96m invested in them.

Commercial M & A

BenevolentAI Scoops $115M For AI Drug Development

At a pre-money valuation of $2bn, BenevolentAI raises $115m to develop artificial intelligence approach that already can cut early drug development timeline by four years.

Artificial Intelligence Financing
See All
Advertisement
UsernamePublicRestriction

Register